Impact of bone and liver metastases (BM, LM) in patients with metastatic renal cell carcinoma (mRCC) treated with molecularly targeted agents (MTAs): Results from the International mRCC Database Consortium (IMDC).

Rana R. McKay(University of California San Diego), Toni K. Choueiri(Harvard University), Sumanta K. Pal(City of Hope), Srinivas K. Tantravahi(University of Utah), Frede Donskov(Aarhus University Hospital), Georg A. Bjarnason(Sunnybrook Health Science Centre), Jae‐Lyun Lee(Ulsan College), Wanling Xie(Dana-Farber Cancer Institute), Jennifer J. Knox(National Cancer Center), Nils Kroeger(Universitätsmedizin Greifswald), Ulka N. Vaishampayan(University of Michigan), Lori Wood(Dalhousie University), Sandy Srinivas(Stanford University), Mary J. MacKenzie(Cancer Care Ontario), Sun Young Rha(Yonsei University), Daniel Yick Chin Heng(University of Calgary), Brian I. Rini(Vanderbilt University Medical Center)
Journal of Clinical Oncology
February 20, 2013
10.1200/jco.2013.31.6_suppl.394
Cited by 2

Related Papers

The Immune Landscape of Cancer
|Immunity|2018|6.3k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k